Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study

BACKGROUND: The once-daily oral combination of daclatasvir (DCV) and sofosbuvir (SOF), with or without ribavirin (RBV), is effective and well tolerated in patients with hepatitis C virus (HCV). However, further field-practice studies are necessary to investigate the effectiveness and safety of the D...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Drugs Context
Autores principales: Sacco, Rodolfo, Messina, Vincenzo, Gentilucci, Umberto Vespasiani, Adinolfi, Luigi Elio, Ascione, Antonio, Barbarini, Giorgio, Barlattani, Angelo, Cariti, Giuseppe, Cozzolongo, Raffaele, Fimiani, Basilio, Francavilla, Ruggiero, Furlan, Caterina, Garrucciu, Giovanni, Iovinella, Vincenzo, Rinaldi, Luca, Marignani, Massimo, Begini, Paola, Palitti, Valeria Pace, Pellicelli, Adriano M, Scifo, Gaetano, Facciorusso, Antonio, Giacomelli, Luca, Shah, Aashni, Bertino, Gaetano, Perazzo, Serena, Bresci, Giampaolo, Izzi, Antonio
Formato: Artigo
Lenguaje:Inglês
Publicado: BioExcel Publishing Ltd 2020
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7747789/
https://ncbi.nlm.nih.gov/pubmed/33408749
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.2020-4-11
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares